Trophos Starts Phase Ib Clinical Trial Of TRO19622 In Spinal Muscular Atrophy

Trophos SA, a biopharmaceutical company specializing in the discovery and development of drugs for neurological disorders, announced that the company has begun enrolling Spinal Muscular Atrophy (SMA) patients in a Phase Ib clinical trial of its lead product, TRO19622. The clinical trial will involve 20 type 1b-3 SMA patients aged between 6 - 25 years of age and will assess the pharmacokinetics and safety of drug product after administration of single and multiple doses, once-daily, by the oral route. The study is being conducted at three centers in France. The clinical program in SMA is supported by the Association Française contre les Myopathies (AFM, http:// www.afm-france.org), through a strategic partnership begun in 2000.